ETFsMSCI World Health Care 35/20 Capped Index
State Street / SPDR

State Street® SPDR® MSCI World Health Care UCITS ETF

WHEA ASAccumulatingPhysical, full replicationIrelandNot PEA-eligible
Last close · EUR
70.86EUR
+0.10% · +€0.07
Published closes: 4 Nov 2026 - 5 Nov 2026
5 Nov 2026, close
WHEABase
Fund charges
0.30%PRIIPs ongoing costs
Fund size
€723.1Mall share classes
Return 1Y
+29.0%Index +14.1%
Sharpe 3Y
0.62Index 1.24
Volatility 1Y
16.0%annualised
Holdings
110Fund holdings

Performance

Compare
  • WHEA+29.0%
  • Price, EUR

Returns

Returns1M3M6MYTD1Y3Y5Y
WHEA+13.6%+16.8%+29.8%+22.6%+29.0%+39.8%+42.4%
MSCI World-2.8%-0.6%+7.8%+14.3%+14.1%+65.6%+64.8%
Gap to MSCI World+16.4%+17.5%+22.0%+8.3%+14.9%-25.8%-22.4%

Risk and return

Sharpe ratio · 3Y
0.62
Below MSCI World · 1.24
Return p.a.
+11.5%
Volatility
14.7%
Max loss
-21.2%Aug 2025

Sharpe vs indices

MSCI World
1.24
S&P 500
1.21
STOXX Europe 600
1.04
MSCI Emerging Markets IMI
0.93
WHEA
0.62
CAC 40
0.37
Method

Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.

Top holdings

Top 10
48.4%
Holdings
110
As of
Fund holdings
  1. 1Eli Lilly and CompanyUS532457108312.17%
  2. 2Johnson & JohnsonUS47816010467.13%
  3. 3AbbVie Inc.US00287Y10915.59%
  4. 4UnitedHealth Group IncorporatedUS91324P10213.99%
  5. 5Merck & Co. Inc.US58933Y10553.98%
  6. 6Roche Holding LtdCH14990599833.65%
  7. 7Novartis AGCH00120052673.23%
  8. 8AstraZeneca PLCGB00098952923.06%
  9. 9Thermo Fisher Scientific Inc.US88355610232.82%
  10. 10Amgen Inc.US03116210092.77%

Countries

Classified 100.0%
Largest
73.9%United States
Top 3
87.9%
Effective number
1.81 / HHI

Market cap

Weight vs holdings

48.4%of the fund sits in the top 10 holdings
  • Holdings 1-10
  • Holdings 11-50
  • Holdings 51-110

Size split

Not published

Compare ETFs in Copio.

ETF comparison in the Copio app, showing costs and returns with illustrative data.

Factual research, without a suitability score or investment recommendation. Past relationships can change.